Haojing is an EIR and the Chief Development Officer of a Stealth NewCo. Prior to this role, she was SVP of Translational Science of Judo Bio focusing on kidney-targeted delivery of oligonucleotide. Before that, she was a VP of Preclinical Development at Kymera Therapeutics. Haojing earned her Ph.D. from Ghent University in Belgium. She worked at Amgen, Merck, Pfizer, and Shire, on programs in neuroscience and rare diseases, including the approval of Lanadelumab and Maribavir. Haojing’s interest and expertise include ADME and Tox knowledge integration for both small molecules and biotherapeutics, particularly human PK and dose projection, applying integrated PK/PD modelling approach in drug development to optimize efficacy and safety.